OBJECTIVE: To assess the efficacy of antimalarial treatment and molecular markers of Plasmodium falciparum resistance in the Chittagong Hill Tracts of Bangladesh. METHODS: A total of 203 patients infected with P. falciparum were treated with quinine 3 days plus sulphadoxine/pyrimethamine (SP) combination therapy, and followed up during a 4-week period. Blood samples collected before treatment were genotyped for parasite mutations related to chloroquine (pfcrt and pfmdr1 genes) or SP resistance (dhfr and dhps). RESULTS: Of 186 patients who completed follow-up, 32 patients (17.2%) failed to clear parasitaemia or became positive again within 28 days after treatment. Recurring parasitaemia was related to age (chi(2) = 4.8, P < 0.05) and parasite rates on admission (t = 3.1, P < 0.01). PCR analysis showed that some of these cases were novel infections. The adjusted recrudescence rate was 12.9% (95% CI 8.1-17.7) overall, and 16.6% (95% CI 3.5-29.7), 15.5% (95% CI 8.3-22.7) and 6.9% (95% CI 0.4-13.4) in three age groups (<5 years, 5-14, > or =15). The majority of infections carried mutations associated with chloroquine resistance: 94% at pfcrt and 70% at pfmdr. Sp-resistant genotypes were also frequent: 99% and 73% of parasites carried two or more mutations at dhfr and dhps, respectively. The frequency of alleles at dhfr, dhps and pfmdr was similar in cases that were successfully treated and those that recrudesced. CONCLUSIONS: The clinical trial showed that quinine 3-days combined to SP is still relatively effective in the Chittagong Hill Tracts. However, if this regimen is continued to be widely used, further development of SP resistance and reduced quinine sensitivity are to be expected. The genotyping results suggest that neither chloroquine nor SP can be considered a reliable treatment for P. falciparum malaria any longer in this area of Bangladesh.
OBJECTIVE: To assess the efficacy of antimalarial treatment and molecular markers of Plasmodium falciparum resistance in the Chittagong Hill Tracts of Bangladesh. METHODS: A total of 203 patients infected with P. falciparum were treated with quinine 3 days plus sulphadoxine/pyrimethamine (SP) combination therapy, and followed up during a 4-week period. Blood samples collected before treatment were genotyped for parasite mutations related to chloroquine (pfcrt and pfmdr1 genes) or SP resistance (dhfr and dhps). RESULTS: Of 186 patients who completed follow-up, 32 patients (17.2%) failed to clear parasitaemia or became positive again within 28 days after treatment. Recurring parasitaemia was related to age (chi(2) = 4.8, P < 0.05) and parasite rates on admission (t = 3.1, P < 0.01). PCR analysis showed that some of these cases were novel infections. The adjusted recrudescence rate was 12.9% (95% CI 8.1-17.7) overall, and 16.6% (95% CI 3.5-29.7), 15.5% (95% CI 8.3-22.7) and 6.9% (95% CI 0.4-13.4) in three age groups (<5 years, 5-14, > or =15). The majority of infections carried mutations associated with chloroquine resistance: 94% at pfcrt and 70% at pfmdr. Sp-resistant genotypes were also frequent: 99% and 73% of parasites carried two or more mutations at dhfr and dhps, respectively. The frequency of alleles at dhfr, dhps and pfmdr was similar in cases that were successfully treated and those that recrudesced. CONCLUSIONS: The clinical trial showed that quinine 3-days combined to SP is still relatively effective in the Chittagong Hill Tracts. However, if this regimen is continued to be widely used, further development of SP resistance and reduced quinine sensitivity are to be expected. The genotyping results suggest that neither chloroquine nor SP can be considered a reliable treatment for P. falciparum malaria any longer in this area of Bangladesh.
Authors: Bernhard Attlmayr; Kamala Thriemer; Rashidul Haque; Yukiko Wagatsuma; Mohammed Abdus Salam; Selim Akhter; Mark Fukuda; Kurt Schaecher; Robert Scott Miller; Harald Noedl Journal: Wien Klin Wochenschr Date: 2006 Impact factor: 1.704
Authors: Hans-Peter Fuehrer; Peter Starzengruber; Paul Swoboda; Wasif Ali Khan; Julia Matt; Benedikt Ley; Kamala Thriemer; Rashidul Haque; Emran Bin Yunus; Shah Monir Hossain; Julia Walochnik; Harald Noedl Journal: Am J Trop Med Hyg Date: 2010-07 Impact factor: 2.345
Authors: Sumiti Vinayak; Md Tauqeer Alam; Tonya Mixson-Hayden; Andrea M McCollum; Rithy Sem; Naman K Shah; Pharath Lim; Sinuon Muth; William O Rogers; Thierry Fandeur; John W Barnwell; Ananias A Escalante; Chansuda Wongsrichanalai; Frederick Ariey; Steven R Meshnick; Venkatachalam Udhayakumar Journal: PLoS Pathog Date: 2010-03-26 Impact factor: 6.823
Authors: Hans-Peter Fuehrer; Paul Swoboda; Josef Harl; Peter Starzengruber; Verena Elisabeth Habler; Ingrid Bloeschl; Rashidul Haque; Julia Matt; Wasif Ali Khan; Harald Noedl Journal: Parasitol Res Date: 2014-02-28 Impact factor: 2.289
Authors: Mohammad Shafiul Alam; Rubayet Elahi; Abu Naser Mohon; Hasan Mohammad Al-Amin; Mohammad Golam Kibria; Wasif A Khan; Hamida Khanum; Rashidul Haque Journal: Am J Trop Med Hyg Date: 2016-05-02 Impact factor: 2.345
Authors: Emily R Derbyshire; Jaeki Min; W Armand Guiguemde; Julie A Clark; Michele C Connelly; Andreia D Magalhães; R Kiplin Guy; Jon Clardy Journal: Antimicrob Agents Chemother Date: 2013-12-23 Impact factor: 5.191
Authors: W Rahman; K Chotivanich; K Silamut; N Tanomsing; A Hossain; M A Faiz; A M Dondorp; R J Maude Journal: Trans R Soc Trop Med Hyg Date: 2009-10-08 Impact factor: 2.184